Recommended Topic Related To:

Optimark

"The U.S. Food and Drug Administration is alerting hospitals, health care professionals, and patients of a voluntary recall of all non-expired drug products produced and distributed for sterile use by Abrams Royal Compounding Pharmacy in Dallas, T"...

OptiMARK

INDICATIONS

CNS (Central Nervous System)

OptiMARK™ Injection is indicated for use with magnetic resonance imaging (MRI) in patients with abnormal blood-brain barrier or abnormal vascularity of the brain, spine and associated tissues.

Liver

OptiMARK™ Injection is indicated for use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.

DOSAGE AND ADMINISTRATION

OptiMARK™ Injection should be administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual or by power injection.

Table 6: Dosage Chart for OptiMARK™ Injection

Body Weight 0.1 mmol/kg Volume (mL)
Kilograms (kg) Pounds (lb)
40 88 8.0
50 110 10.0
60 132 12.0
70 154 14.0
80 176 16.0
90 198 18.0
100 220 20.0
110 242 22.0
120 264 24.0
130 286 26.0
140 308 28.0
150 330 30.0

Imaging

The imaging procedure should be completed within 1 hour of the injection of OptiMARK™ Injection. The safety of repeat doses has not been studied. OptiMARK™ MRI images should be interpreted in comparison to unenhanced MRI (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Trials).

Drug Handling

Parenteral products should be inspected visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present.

Concurrent medications or Parenteral Nutrition should not be physically mixed with contrast agents and should not be administered in the same intravenous line because of the potential for chemical incompatibility.

When OptiMARK™ Injection is to be injected using plastic disposable syringes, the contrast should be drawn into the syringe and used immediately.

This product has not been evaluated for use in magnetic resonance angiography.

OptiMARK™ Injection should be drawn into the syringe and administered using sterile technique. If nondisposable equipment is used, scrupulous care should be taken to prevent residual contamination with traces of cleansing agents. To ensure complete injection of the contrast medium the injection should be followed by a 5 mL normal saline flush. Unused portions of the drug must be discarded.

HOW SUPPLIED

OptiMARK™ Injection is a clear, colorless to slightly yellow solution containing 330.9 mg/mL, 0.5 mmol/mL of gadoversetamide. OptiMARK™ Injection is supplied in 10 mL vials containing 5 mL or 10 mL of solution and is also provided in 20 mL vials containing 15 mL or 20 mL of solution. Each single dose vial is rubber stoppered with an aluminum seal and the contents are sterile. OptiMARK™ Injection is supplied in 10 mL, 15 mL, 20 mL or 30 mL syringes containing 10 mL, 15 mL, 20 mL or 30 mL of solution respectively. Each syringe is sealed with rubber closures and the contents are sterile. Vials and syringes are contained in shipping cartons with the following configurations:

5 mL in glass vials in cartons of 10 vials
(NDC Code 0019-1177-02)

10 mL in glass vials in cartons of 10 vials
(NDC Code 0019-1177-04)

15 mL in glass vials in cartons of 10 vials
(NDC Code 0019-1177-06)

20 mL in glass vials in cartons of 10 vials
(NDC Code 0019-1177-08)

10 mL in plastic syringes in cartons of 10 syringes
(NDC Code 0019-1177-11)

15 mL in plastic syringes in cartons of 10 syringes
(NDC Code 0019-1177-16)

20 mL in plastic syringes in cartons of 10 syringes
(NDC Code 0019-1177-21)

30 mL in plastic syringes in cartons of 10 syringes
(NDC Code 0019-1177-31)

Storage

OptiMARK™ Injection should be stored at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature] and protected from light and freezing. OptiMARK™ Injection may be stored at 37°C for up to one month in a contrast media warmer utilizing circulating warm air. For periods longer than one month, store at 20°C to 25°C (68°F to 77°F).

Manufactured and Distributed by: Mallinckrodt Inc., St. Louis, MO 63042 U.S.A. Mallinckrodt Inc. St. Louis, MO 63042 U.S.A. www.Mallinckrodt.com. Revised 05/13

Last reviewed on RxList: 9/9/2013
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations